

## Special Issue

# Oncolytic Viruses and Combinatorial Immunotherapy for Cancer

### Message from the Guest Editors

Oncolytic viruses (OVs) are developed as tools for novel cancer therapies. In recent years, investigators have started to realize that the indirect antitumor activity of viruses beyond direct oncolysis is a vital contributor to therapeutic efficacy. OV-induced antitumor immunity plays an important, sometimes essential, role in OV-mediated therapeutics for cancer. OVs modulate the tumor microenvironment to favor antitumor immunity. Their ability to turn cold tumors immunologically hot is a unique property that makes OVs highly useful agents in combinatorial approaches for cancer immunotherapy. We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-advancing field of biomedicine. The submission of articles addressing (i) the mechanisms of action of OVs, (ii) genetic modifications of OVs for improving their efficacy and safety, (iii) the delivery of OVs, (iv) host responses to OVs and (v) studies with combinatorial approaches is strongly encouraged.

### Guest Editors

Dr. Zong Sheng Guo

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Dr. Michael H. Lehmann

Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität München, 85764 Oberschleißheim, Germany

### Deadline for manuscript submissions

closed (30 April 2025)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/183928](https://mdpi.com/si/183928)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).